Skip to content
OpenCapital
Get started

Polaryx Therapeutics, Inc. PLYX Accrued Manufacturing Costs

Accrued Manufacturing Costs at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
——

Other financials

Income statement

See full
Operating income-$2.0M+61.2%
Net income-$2.5M+49.6%
EPS (diluted)-$0.05+54.5%

Balance sheet

See full
Cash & equivalents$3.1M+1,132%
Total equity$2.5M-41.5%
Total assets$3.5M—

Cash flow

See full
Operating cash flow-$2.1M-191%

Valuation

See full
Market cap$132.59M-86.9%

Returns & leverage

See full
Return on equity-1,209.8%—
Current ratio3.5×—

Where this comes from

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The official record: Polaryx Therapeutics, Inc. ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Polaryx Therapeutics, Inc. 's accrued manufacturing costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Polaryx Therapeutics, Inc. 's accrued manufacturing costs?
Polaryx Therapeutics, Inc. (PLYX) reported accrued manufacturing costs of $21K in Q1 2026.